These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

456 related articles for article (PubMed ID: 27400643)

  • 21. Is it time to move away from polymyxins?: evidence and alternatives.
    Soman R; Bakthavatchalam YD; Nadarajan A; Dwarakanathan HT; Venkatasubramanian R; Veeraraghavan B
    Eur J Clin Microbiol Infect Dis; 2021 Mar; 40(3):461-475. PubMed ID: 33009595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of multidrug-resistant Gram-negative skin and soft tissue infections.
    Jabbour JF; Sharara SL; Kanj SS
    Curr Opin Infect Dis; 2020 Apr; 33(2):146-154. PubMed ID: 32022742
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing Clinician Utilization of Next-Generation Antibiotics Against Resistant Gram-Negative Infections in U.S. Hospitals : A Retrospective Cohort Study.
    Strich JR; Mishuk A; Diao G; Lawandi A; Li W; Demirkale CY; Babiker A; Mancera A; Swihart BJ; Walker M; Yek C; Neupane M; De Jonge N; Warner S; Kadri SS;
    Ann Intern Med; 2024 May; 177(5):559-572. PubMed ID: 38639548
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria.
    Giacobbe DR; Mikulska M; Viscoli C
    Expert Rev Clin Pharmacol; 2018 Dec; 11(12):1219-1236. PubMed ID: 30444147
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [New β‑lactam antibiotics and β‑lactamase inhibitors against multidrug-resistant Gram-negative bacteria].
    Mischnik A; Lübbert C; Mutters NT
    Internist (Berl); 2018 Dec; 59(12):1335-1343. PubMed ID: 30264191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging Gram negative resistance to last-line antimicrobial agents fosfomycin, colistin and ceftazidime-avibactam - epidemiology, laboratory detection and treatment implications.
    Sherry N; Howden B
    Expert Rev Anti Infect Ther; 2018 Apr; 16(4):289-306. PubMed ID: 29543500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Defining the Role of Novel β-Lactam Agents That Target Carbapenem-Resistant Gram-Negative Organisms.
    Tamma PD; Hsu AJ
    J Pediatric Infect Dis Soc; 2019 Jul; 8(3):251-260. PubMed ID: 30793757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cephalosporins currently in early clinical trials for the treatment of bacterial infections.
    Long TE; Williams JT
    Expert Opin Investig Drugs; 2014 Oct; 23(10):1375-87. PubMed ID: 24956017
    [TBL] [Abstract][Full Text] [Related]  

  • 29. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies.
    Lodise TP; Bassetti M; Ferrer R; Naas T; Niki Y; Paterson DL; Zeitlinger M; Echols R
    Expert Rev Anti Infect Ther; 2022 May; 20(5):707-719. PubMed ID: 34937518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens.
    Hornsey M; Phee L; Stubbings W; Wareham DW
    Int J Antimicrob Agents; 2013 Oct; 42(4):343-6. PubMed ID: 23837926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Colistin: still a lifesaver for the 21st century?
    Karaiskos I; Souli M; Galani I; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2017 Jan; 13(1):59-71. PubMed ID: 27573251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of new β-lactamase inhibitors in gram-negative infections.
    Vena A; Castaldo N; Bassetti M
    Curr Opin Infect Dis; 2019 Dec; 32(6):638-646. PubMed ID: 31577557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activity of Meropenem Combined with RPX7009, a Novel β-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City.
    Lapuebla A; Abdallah M; Olafisoye O; Cortes C; Urban C; Quale J; Landman D
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4856-60. PubMed ID: 26033723
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Investigational drugs for the treatment of infections caused by multidrug-resistant Gram-negative bacteria.
    Avery LM; Nicolau DP
    Expert Opin Investig Drugs; 2018 Apr; 27(4):325-338. PubMed ID: 29611447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An update on the management of urinary tract infections in the era of antimicrobial resistance.
    Bader MS; Loeb M; Brooks AA
    Postgrad Med; 2017 Mar; 129(2):242-258. PubMed ID: 27712137
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multidrug-resistant gram-negative organisms: a review of recently approved antibiotics and novel pipeline agents.
    Provenzani A; Hospodar AR; Meyer AL; Leonardi Vinci D; Hwang EY; Butrus CM; Polidori P
    Int J Clin Pharm; 2020 Aug; 42(4):1016-1025. PubMed ID: 32638294
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Multidrug-resistant Gram-negative bacteria: how to treat and for how long.
    Giamarellou H
    Int J Antimicrob Agents; 2010 Dec; 36 Suppl 2():S50-4. PubMed ID: 21129924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge?
    Curcio D
    Curr Clin Pharmacol; 2014 Feb; 9(1):27-38. PubMed ID: 23489027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New antibacterial agents for treating infections caused by multi-drug resistant Gram-negative bacteria.
    O'Neill AJ
    Expert Opin Investig Drugs; 2008 Mar; 17(3):297-302. PubMed ID: 18321229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluating imipenem + cilastatin + relebactam for the treatment of complicated urinary tract infections.
    Kuiper SG; Leegwater E; Wilms EB; van Nieuwkoop C
    Expert Opin Pharmacother; 2020 Oct; 21(15):1805-1811. PubMed ID: 32820669
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.